Results 241 to 250 of about 462,488 (300)

Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders. [PDF]

World J Gastrointest Pharmacol Ther
Goyal O, Chowdhary R, Sehgal T, Joshi T, Bhambri A, Rampurawala IM, Sohi GS, Das A, Arora K, Vuthaluru AR, Goyal MK.   +10 more
europepmc   +1 more source

Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. [PDF]

Oncologist
Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, Elshaer A, Shaik A, Baroudi M, Moudgil R, Mustafa Ali MK.   +10 more
europepmc   +1 more source

Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease - from Pathophysiology to Effective Management Overview. [PDF]

Int J Chron Obstruct Pulmon Dis
Prisacaru V, Covantsev S, Ceasovschih A, Sivapalan P, Tural S, Corlateanu A, Deleanu OC.   +6 more
europepmc   +1 more source

Oral Antidiabetic Agents and Cardiovascular Outcomes

Current Problems in Cardiology, 2018
Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes; however, a direct protective effect of tight glycemic control remains unproven. In fact, until 2008, when concerns related to rosiglitazone prompted regulatory agencies to mandate assessment of cardiovascular safety of new antidiabetic agents ...
Pareek, Manan, Bhatt, Deepak L
openaire   +3 more sources

Cardiovascular Agents

Seminars in Dialysis, 2010
With a growing population of patients with chronic kidney disease (CKD), it is critical that clinicians are aware of the consequences of how kidney failure affects the pharmacokinetics and pharmacodynamics of cardio- vascular medications.
Ted Walton, Rebekah Thomas
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Cardiovascular Agents

2021
Frank A Maffei, Maffei Frank A
exaly   +2 more sources